ASH 2024 | Key MPN trials to look out for in 2025

There are a lot of trials being updated at this ASH meeting. So just very quickly, there’s the Incyte BET inhibitor, there is the Sumitomo PIM kinase inhibitor that I’m certainly watching closely as the data evolve and are updated with more and more patients. Both are very active drugs that could go on to later phase trials. And then, you know, there are, for example, in systemic mastocytosis, there are bezuclastinib data being updated in both the advanced setting and the non-advanced setting. Navtemadlin has two oral presentations this year at ASH. That’s the MDM2 inhibitor from Kartos, oral agent being developed in the suboptimal setting, you know, in patients who’ve been on ruxolitinib. Intriguing presentation from my colleague from MD Anderson, Lucia Masarova, on umbilical cord-derived T-cell, regulatory T-cells in myelofibrosis. So a lot of these agents, you know, are still somewhat early. For example, this one, you know, it’s a small presentation on nine patients. But then you have the others that I mentioned, you know, the BET inhibitor, the PIM kinase inhibitor, navtemadlin. Obviously, a lot of interest around these and we’re going to watch these going forward. Elritercept is a novel active in receptor ligand trap from a company called Keros, which is designed for anemia of both myelofibrosis and MDS. That’s being also presented by Claire Harrison. So all of these are drugs to watch. But I would also say, you know, if you look at the agents that are already in Phase III, I think it’s helpful to just quickly enumerate those. So imetelstat in the post-JAK inhibitor, sort of JAK inhibitor failure setting, that’s the IMpactMF trial, waiting for the results of that. Luspatercept for anemia in transfusion requiring patients on JAK inhibitors, that’s in a fully accrued Phase III, so we await the results of those. We just talked about navtemadlin, that’s in the suboptimal setting, getting started with its Phase III trial. And then there’s selinexor. You know a lot of excitement around that in the frontline setting with ruxolitinib versus ruxolitinib and placebo. So all these different trials are all in phase three so all are pretty advanced but as you can see in different sort of settings you know you have JAK inhibitor failure, you have suboptimal, you have frontline, you have anemia directed. So these are the agents in Phase III testing right now and then we already talked about the earlier agents.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.